Chronic Lymphocytic Leukemia: New Horizons with BTK Inhibitors

Chronic Lymphocytic Leukemia: New Horizons with BTK Inhibitors (May 2020)

Saturday, May 30, 2020 in Chicago, Illinois
Dinner -- Sheraton Grand Chicago, 6:30 PM CT

Agenda

6:30 PM – 7:00 PM Dinner and Registration

7:00 PM – 9:00 PM Chronic Lymphocytic Leukemia: New Horizons with BTK Inhibitors

  • Overview of the BCR Pathway and BTK in Tumor Development
  • Safety and Efficacy of BTK inhibitors in The Management of B-Cell Malignancies (Ibrutinib, Acalabrutinib, Zanubrutinib)
  • BTK Inhibitors in Treatment-Naive CLL
    • Includes case-based discussions
  • BTK inhibitors in Relapsed/Refractory CLL
    • Includes case-based discussions
  • BTK Inhibitors beyond CLL
  • Summary, Final Thoughts, and Audience Question and Answer Session

Faculty

Program Chair
Jeff Sharman, MD

Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Faculty
Danielle Brander, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Faculty
Nicole Lamanna, MD

Associate Attending
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate BTK inhibitors into the treatment of patients with CLL.

Target Audience
This program is intended for hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with CLL and other B-cell malignancies.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, selectivity, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Delineate the variables to be considered in selecting treatment for CLL including tumor characteristics such as biomarkers and patient characteristics and preferences
  • Describe clinical trial results providing evidence for the important role of BTK inhibitor based combinations in first-line treatment of CLL including phase III and phase II trials
  • Select patients most likely to benefit from continuous first-line treatment options and those patients most likely to benefit from time-limited first line options
  • Plan optimal, individualized therapeutic strategies for patients CLL taking into consideration recent practice-changing clinical trial results
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.